Background Allergic rhinitis is a disease underestimated by patients, and underdiagnosed and thus undertreated by physicians since most of the patients present with symptoms of moderate-to-severe disease, overall diminished quality of life, impairing sleep quality and cognitive function, and a substantial impact on work productivity, school absenteeism, and costs. The relationship between treating physician and patients is crucial in all chronic diseases. Objectives Review the main changes and innovations of recent years in the ARIA guide- lines. Methods The most recent publications of the ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines were reviewed. Results ARIA 2016 strengthens the role of patients in the control and treatment of their symptoms by the use of technology, which improves physician-patient communication. The selection of pharmacotherapy for patients with allergic rhinitis (AR) depends on several factors, including age, prominent symptoms, symptom severity, control of AR, patient preferences, and cost. It confirms that inhaled corticosteroids are the most effective drugs for the management of seasonal or perennial allergic rhinitis, not surpassed by combination therapies with oral or topical antihistamines. On the other hand, no significant differences between the use of oral or topical antihistamines are evidenced. Allergen exposure and the resulting symptoms
Current Treatment Options in Allergy – Springer Journals
Published: May 16, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera